Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences has signed a license agreement with Tibotec Pharmaceuticals to develop and market a single-tablet regimen comprising Prezista (darunavir), Gilead's Emtriva (emtricitabine, GS7340) and a pharmacoenhancer cobicistat.
Subscribe to our email newsletter
As per the deal, Gilead will be responsible for the formulation, manufacturing, registration, distribution and commercialisation of the single-tablet regimen worldwide, while Tibotec will co-detail the single-tablet regimen in certain major markets.
Gilead Sciences chief scientific officer Norbert Bischofberger said for the first time they are developing a protease inhibitor-containing single-tablet regimen, due to the small milligram size of GS 7340.
GS 7340, Gilead’s investigational anti-HIV agent, is a novel prodrug of tenofovir, the active agent in the company’s HIV drug Viread (tenofovir disoproxil fumarate).
The company is likely to commence a Phase 2 study of GS 7340 in early 2012.